CancerJun 4, 2026
CA 19-9 is the most validated blood marker for pancreatic cancer, yet it catches only about 72–80% of symptomatic cases and flags plenty of people who don't have cancer at all. It's a genuinely useful tool in the right context, but it's also widely misunderstood. If your doctor ordered this test, or if a result came back high (or suspiciously normal), understanding what CA 19-9 can and can't tell you matters more than the number on the page.
CancerJun 4, 2026
The clinical trial that won Cologuard FDA approval enrolled 9,989 people, each of whom collected a stool sample at home before their colonoscopy. Not one of them was told to skip red meat, avoid raw broccoli, or stop their vitamin C beforehand. The same was true in the 20,176-person trial of the next-generation version of the test.
That isn't a study oversight. It's the entire point of how Cologuard is built. The test looks for things that only come from your own gut, not from your last meal, so dietary prep would be redundant.
Digestive DisordersJun 4, 2026
About 60% of adults with lymphocytic colitis experience a single episode that resolves on its own. That's a striking number for a condition that can cause weeks or months of relentless watery diarrhea, urgency, and real disruption to daily life. But here's the catch: because the colon looks perfectly normal during a standard colonoscopy, many people cycle through appointments and tests before anyone thinks to take a biopsy. Without that biopsy, lymphocytic colitis is invisible.
Lymphocytic colitis (LC) is a form of microscopic colitis, meaning the inflammation only shows up under a microscope. It typically strikes middle-aged to older adults, with a median age around 59 to 67 years, and is more common in women. The hallmark is chronic, watery, non-bloody diarrhea, often accompanied by abdominal pain, weight loss, and sometimes fecal incontinence. It can significantly affect quality of life even though it carries a largely benign prognosis.
Cancer ScreeningJun 4, 2026
Cologuard detects about 92% of colorectal cancers from a stool sample you collect at home. That's genuinely impressive. But here's the critical distinction most people miss: catching cancer is not the same as preventing it. Colonoscopy can find precancerous polyps and remove them during the same procedure, stopping cancer before it starts. Cologuard can flag some of those polyps but can't do anything about them, and it misses a substantial number of the advanced ones colonoscopy would catch.
Both tests are guideline-endorsed options for average-risk adults. The choice between them isn't about one being "good" and the other "bad." It's about understanding what each test actually does, what it misses, and what happens after you get a result.
BiomarkersJun 4, 2026
A normal fecal calprotectin result has excellent negative predictive value for ruling out inflammatory bowel disease. In practical terms, that means if your doctor suspects your chronic gut symptoms might be IBD but your fecal calprotectin comes back normal, you may be able to skip the colonoscopy entirely. For the millions of people living with unexplained abdominal pain, bloating, and altered bowel habits, that distinction between "inflamed gut" and "irritated gut" is one of the most consequential calls in gastroenterology.
Fecal calprotectin isn't a new or experimental test. It's a well-validated, non-invasive biomarker that has become a cornerstone tool for differentiating functional bowel disorders like irritable bowel syndrome from true inflammatory disease, and for tracking IBD once diagnosed. But like any test, it has blind spots worth understanding before you see your results.
ColonoscopyJun 4, 2026
Most people assume colonoscopy prep means days of dietary misery. The research tells a different story. For generally healthy, average-risk outpatients using a modern split-dose bowel prep, prospective data show no association between what you eat 2 to 3 days before the procedure and how clean your bowel ends up being.
That means the restrictive eating many people dread can usually be compressed into a single day, not two or three. Several randomized trials and meta-analyses back this up: extending a low-residue or low-fiber diet beyond one day before the colonoscopy does not improve prep quality. It just makes the whole process harder to follow.
Liver HealthJun 4, 2026
End-stage liver disease doesn't announce itself with one unmistakable symptom. It shows up as a combination of serious problems that accumulate as the liver loses its ability to function. The tricky part is that severe liver damage develops gradually and the individual symptoms aren't specific, meaning each one on its own could point to something else entirely. It's the pattern that matters.
That pattern typically includes jaundice, fluid build-up, confusion or personality changes, bleeding problems, extreme fatigue, breathing difficulty, and a handful of other late-stage signs. If several of these appear together, treat them as a medical emergency, not a puzzle to solve on your own.
Irritable Bowel SyndromeJun 4, 2026
Most drugs for irritable bowel syndrome with constipation (IBS-C) get absorbed into your bloodstream and work from the inside out. Ibsrela (tenapanor) takes the opposite approach. It acts almost entirely within the gut itself, with very low absorption into the body. That local-only design is central to both how it works and why its safety profile looks the way it does.
FDA-approved in 2019, Ibsrela at 50 mg twice daily improved both constipation and abdominal pain in trials involving more than 1,200 adults. The trade-off is straightforward: diarrhea is the most common side effect, but it tends to be mild to moderate and shows up early rather than building over time.
CancerJun 4, 2026
The next-generation version of Cologuard catches roughly 94% of colorectal cancers from a single stool sample collected on your bathroom counter. That sentence sounds like marketing copy, but it comes from a meta-analysis of 55 studies comparing the multi-target stool DNA test against colonoscopy as the reference standard.
If your doctor has handed you a kit, or you ordered one yourself, the next question is mechanical. What do you actually do with this box? Below is the full set of Cologuard instructions, what each step is checking for, and what the evidence says about how the test performs when used the way it was designed to be used.
Ulcerative ColitisJun 4, 2026
About one in four people diagnosed with limited ulcerative colitis will see their disease creep upward to involve the entire colon within a decade. That progression, called pancolitis, isn't just a change in geography. It marks a shift toward higher relapse rates, more hospitalizations, greater odds of surgery, and an elevated risk of colorectal cancer. If you or someone you care about has UC, understanding what pancolitis means practically is worth the time.
Pancolitis refers to continuous inflammation stretching from the rectum all the way through the proximal (upper) colon. It affects roughly 20 to 40% of people with UC, making it the most extensive form of the disease. And while the name sounds dramatic, what really matters is how it changes the playbook for monitoring, treatment, and long-term risk.
Gastrointestinal HealthJun 4, 2026
When researchers spiked stool samples with known pathogens and ran them through the Diagnostic Solutions GI-MAP assay, the test correctly detected what was there about 80% of the time. That sounds decent until you see the other number: specificity landed at just 26 to 27%. That means for every sample where a pathogen was genuinely absent, the GI-MAP test still reported a positive result roughly three out of four times. Those aren't rounding errors. Those are false positives that could lead directly to antimicrobial prescriptions you never needed.
The GI-MAP is one of the most popular stool tests in functional medicine, used to profile gut bacteria, flag pathogens, and paint a picture of your microbiome. But popularity and accuracy aren't the same thing, and the independent data on this specific test tell a story worth understanding before you hand over your credit card or start a treatment protocol based on the results.
ColonoscopyJun 4, 2026
Colonoscopy was not designed with women's bodies in mind, and the data reflects it. Women have anatomically longer, more redundant colons that make the procedure technically more difficult. They report more pain. Their colorectal lesions are harder to detect. And perhaps most critically, a negative colonoscopy after a positive stool test reduces subsequent colorectal cancer incidence in men but offers a much weaker, or even absent, protective effect in women.
These aren't minor footnotes. They point to real, measurable gaps in how well colonoscopy serves half the population, from the moment of referral through follow-up.
Digestive DisordersJun 3, 2026
Diverticulitis doesn't produce a single, recognizable stool appearance. If you're scanning the toilet bowl looking for a visual clue that confirms a diagnosis, research simply doesn't support that approach. What the evidence does show is that diverticular disease changes how often you go, how loose your stool is, and how long those shifts can linger, sometimes for months after an acute episode resolves.
That distinction matters more than it sounds. Complications like perforation, abscess, or fistula are diagnosed with CT imaging, not by looking at stool. So the real value isn't in identifying a specific appearance. It's in recognizing when your bowel habits have shifted in a way that deserves attention.
Urinary HealthJun 3, 2026
Alkaline urine can inflate your urobilinogen result from roughly 30% of the filtered load to over 100%, without any change in what's actually circulating in your blood. That single fact should make you think twice before reading too much into a urobilinogen value on a routine urinalysis. The number on the strip reflects a tangle of variables: how much bilirubin your body produces, which bacteria live in your gut, when during the day you collected the sample, and the pH of your urine at that moment.
Urobilinogen is a colorless compound your gut bacteria make by breaking down bilirubin, the waste product of old red blood cells. A small amount normally shows up in urine. But "normal" is doing a lot of heavy lifting here, because what actually lands in the cup depends on a chain of biological steps, each with its own set of disruptors.
CancerJun 3, 2026
In the trial that won Cologuard FDA approval, the test found 92.3% of colorectal cancers and 42.4% of advanced precancerous polyps in nearly 10,000 average-risk adults. That single split tells you almost everything about how to think about it.
The test is excellent at catching cancer that already exists. It is much less reliable at finding the polyps that might quietly turn into cancer over the next decade.
That distinction matters because most colorectal cancer screening is really about removing precursors before they become anything serious. So "is Cologuard accurate?" depends on which question you are actually asking the test.
CancerJun 3, 2026
No study has reported a cancer risk signal for psyllium husk. Not in humans, not in animals, not in lab work. If you've been searching for a psyllium husk cancer warning, the research simply doesn't contain one. What it does contain is a growing body of experimental evidence suggesting psyllium may actually work against cancer, particularly in the colon. The real safety concerns are decidedly less dramatic, but still worth paying attention to.
That disconnect between fear and evidence is worth unpacking, because the actual risks of psyllium husk are the ones most people never think to ask about.
InfectionsJun 3, 2026
C. diff is unquestionably contagious. It spreads through a fecal-oral route, meaning spores from an infected person's stool end up on hands, surfaces, or objects, and someone else swallows them. What makes C. diff particularly stubborn is that its spores can survive on surfaces for months, turning rooms, toilets, and shared equipment into lasting reservoirs of infection.
But the part most people miss: you don't have to be visibly sick to spread it. A significant number of people carry toxigenic C. diff without any symptoms at all. These asymptomatic carriers shed spores and contaminate their surroundings, acting as silent sources of ongoing transmission in hospitals, long-term care facilities, and homes.
Gastrointestinal HealthJun 3, 2026
A small clinical trial found no extra symptom benefit when lactose-intolerant adults ate lactose-free yogurt compared to regular yogurt, as long as both contained high levels of live cultures. That finding reframes the entire conversation. Regular yogurt is already naturally lower in lactose than milk, and its bacteria actively help break down whatever lactose remains.
That doesn't make lactose-free yogurt pointless. It does mean the decision is more nuanced than "I'm lactose intolerant, so I need the lactose-free version." Here's what the research actually supports.
Digestive DisordersJun 3, 2026
Psyllium, the single ingredient in Metamucil, has clinical trial evidence behind four distinct health outcomes: relieving constipation, lowering LDL cholesterol, improving blood sugar control in type 2 diabetes, and supporting modest weight loss. That makes it one of the best-studied fiber supplements you can buy.
The catch is that these results consistently require around 10 grams per day or more, taken for at least several weeks. A single spoonful on a random Tuesday morning probably isn't doing much.
CancerJun 3, 2026
Cologuard catches more than 9 out of 10 colorectal cancers but only about 4 out of 10 advanced precancerous lesions. That asymmetry is the most important thing to understand about how the test works, and it explains both why Cologuard exists and why colonoscopy hasn't been replaced.
If you're choosing between screening options, accuracy isn't a single number. It's a trade-off: how often the test correctly flags cancer, how often it catches polyps before they turn into cancer, and how often it cries wolf. Cologuard handles those three things very differently from each other, and the numbers have shifted with the next-generation version.
